Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 12/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.44 |
| ▸ | PTGES | O14684 | 2/20 | 0.44 |
| ▸ | LIPE | Q05469 | 2/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30786460 | 1.00 | MRGPRX4 (0.47) | MRGPRX4ALOX5PTGESLIPEENPP2 | |
| SCHEMBL17236437 | 0.85 | LIPE (0.50) | MRGPRX4LIPEENPP2 | |
| SCHEMBL13144435 | 0.83 | MRGPRX4 (0.47) | MRGPRX4ALOX5PTGES | |
| SCHEMBL2560808 | 0.82 | ENPP2 (0.52) | MRGPRX4LIPEENPP2HDAC8 | |
| SCHEMBL27094577 | 0.81 | SLC6A4 (0.49) | MRGPRX4ALOX5PTGES | |
| SCHEMBL2558927 | 0.81 | MAPT (0.46) | MRGPRX4LIPEENPP2HDAC8 | |
| SCHEMBL16687431 | 0.80 | ENPP2 (0.41) | MRGPRX4LIPEENPP2HDAC8 | |
| SCHEMBL2561187 | 0.79 | TP53 (0.56) | MRGPRX4LIPEENPP2HDAC8 | |
| SCHEMBL2560802 | 0.77 | MCL1 (0.51) | MRGPRX4PTGES | |
| SCHEMBL24831692 | 0.77 | MRGPRX4 (0.44) | MRGPRX4ALOX5PTGESHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208922-A1 | A TRIFLUOROMETHYL THIANTHRENIUM COMPOUND, PROCESS FOR PREPARING THE SAME AND THE USE THEREOF | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2024-06-27 | — | — | US | disclosed |
| US-20240208922-A1 | A TRIFLUOROMETHYL THIANTHRENIUM COMPOUND, PROCESS FOR PREPARING THE SAME AND THE USE THEREOF | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2024-06-27 | — | — | US | disclosed |
| US-20240208922-A1 | A TRIFLUOROMETHYL THIANTHRENIUM COMPOUND, PROCESS FOR PREPARING THE SAME AND THE USE THEREOF | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2024-06-27 | — | — | US | disclosed |
| EP-4323348-A1 | A TRIFLUOROMETHYL THIANTHRENIUM COMPOUND, PROCESS FOR PREPARING THE SAME AND THE USE THEREOF | Studiengesellschaft Kohle gGmbH (DE) | 2024-02-21 | — | — | EP | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | MRGPRX4 243/4885ALOX5 2253/4885PTGES 573/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | MRGPRX4 243/4885ALOX5 2253/4885PTGES 573/4885 |
| US-20240208922-A1 | A TRIFLUOROMETHYL THIANTHRENIUM COMPOUND, PROCESS FOR PREPARING THE SAME AND THE USE THEREOF | CYP4F3, GTF3C3, GTF3C4 | MRGPRX4 705/4885ALOX5 2953/4885PTGES 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.